Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome)

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 3, 2011, Pages 253-258

  Papadia, F ^a   Lozupone, M S ^a   Gaeta, A ^b   Capodiferro, D ^a   Lacalendola, G ^b  

^a Unity of Metabolic Genetic Diseases   (Italy)

^b Pediatric Hospital Giovanni XXIII   (Italy)

Author keywords

Enzyme replacement therapy; Iduronate 2 sulfatase; Idursulfase; Mucopolysaccharidosis type II

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE; BIOLOGICAL MARKER; GLYCOPROTEIN; IDS PROTEIN, HUMAN; RECOMBINANT PROTEIN;

AORTA STENOSIS; BONE REMODELING; BRAIN ATROPHY; CASE REPORT; CHILD; CLINICAL EXAMINATION; DETERIORATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; GENETIC ANALYSIS; HEPATOMEGALY; HUMAN; HUNTER SYNDROME; LANGUAGE DISABILITY; LONG TERM CARE; MALE; MITRAL VALVE STENOSIS; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SCHOOL CHILD; SPLENOMEGALY; SYSTOLIC HEART MURMUR; TREATMENT DURATION; URINARY EXCRETION; ARTICLE; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HOSPITALIZATION; PRESCHOOL CHILD; TIME; TREATMENT OUTCOME; URINE;

BIOLOGICAL MARKERS; BONE REMODELING; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ENZYME REPLACEMENT THERAPY; GLYCOPROTEINS; GLYCOSAMINOGLYCANS; HUMANS; MALE; MUCOPOLYSACCHARIDOSIS II; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 79957989386     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. MARTIN R, BECK M, ENG C, GIUGLIANI R, HARMATZ P, MUNOZ V, MUENZER J. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008; 121: 377-386.
2. WRAITH JE, SCARPA M, BECK M, BODAMER OA, DE MEIRLEIR L, GUFFON N, MELDGAARD LUND A, MALM G, VAN DER PLOEG AT, ZEMAN J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167: 267-277.
3. BURROW TA, LESLIE ND. Review of the use of idursulfase in the treatment of mucopolysaccharidosis II. Biologics 2008; 2: 311-320.
4. TAYLOR C, BRADY P, O'MEARA A, MOORE D, DOWLING F, FOGARTY E. Mobility in Hurler syndrome. J Ped Orthop 2008; 28: 163-168. (Pubitemid 351498922)
5. MASTERON EL, MURPHY PG, O'MEARA A, MOORE DP, DOWLING FE, FOGARTY EE. Hip displasya in Hurler's syndrome: orthopaedic management after bone marrow transplantation. J Ped Orthop 1996; 16: 731-733. (Pubitemid 26353391)
6. BOROWSKY A, THACKER MM, MACKENZIE WG, LITTLETON AG, GRISSOM L. The use of CT to access acetabular morphology in Morquio syndrome. J Ped Orthop 2007; 27: 893-897.
7. LINK B, MIEBACH E, SCHMITT D, BECK M, MEURER A. Mucopolysaccharidosis. Orthopade 2008; 37: 24-30.
8. COPPA GV, GABRIELLI O, ZAMPINI L, JETZEQUEL AM, MINIERO R, BUSCA A, DE LUCA T, DI NATALE P. Bone marrow transplantation in Hunter syndrome. J Inherit Metab Dis 1995; 18: 91-92.
9. MCKINNIS EJ, SULZBACHER S, RUTLEDGE JC, Sanders J, Scott CR. Bone marrow transplantation in Hunter syndrome. J Pediatr 1996; 129:145-148. (Pubitemid 26277259)
10. MULLEN CA, THOMPSON JN, RICHARD LA, CHAN KW. Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia. Bone Marrow Transplant 2000; 25: 1093-1097.
11. FROISSART R, MOREIRA DA SILVA I, GUFFON N, BOZON D, MAIRE I. Mucopolysaccharidosis type II-genotype/ phenotype aspects. Acta Paediatr Suppl. 2002; 91: 82-87. (Pubitemid 36174157)
12. GALÁN-GÓMEZ E, GUERRERO-RICO A, CÁCERES-MARZAL C, ZAMBRANO-CASTAÑO M, MORENO-TEJERO ML, GRANDE-TEJADA AM, FERNÁNDEZ-HERNÁNDEZ S, VAQUERIZO- MADRID J, CARDESA-GARCÍA JJ. Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome. Eur J Med Gen 2008; 51: 268-271.
13. BAGEWADI S, ROBERTS J, MERCER J, JONES S, STEPHENSON J, WRAITH JE. Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. J Inherit Metab Dis 2008; 31: 733-737.
14. HOPPENFIELD S. L'esame obbiettivo dell'apparato locomotore. Aulo Gaggi Editore, Bologna, 1976.
15. SHAPIRO EG, LOCKMAN LA, BALTHAZOR M, KRIVIT W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995; 18: 413-429.
16. VELLODI A, YOUNG E, COOPER A, LIDCHI V, WINCHESTER B, WRAITH JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 2009; 22: 638-648.
17. PETERS C, KRIVIT W. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome); an ethical commentary. Bone Marrow Transplant 2000; 25: 1097-1099.
18. MUENZER J, WRAITH JE, BECK M, GIUGLIANI R, HARMATZ P, ENG CM, VELLODI A, MARTIN R, RAMASWAMI U, GUCSAVAS-CALIKOGLU M, VIJAYARAGHAVAN S, WENDT S, PUGA A, ULBRICH B, SHINAWI M, CLEARY M, PIPER D, CONWAY AM, KIMURA A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8: 465-473.
19. NATIONAL MPS SOCIETY. Orthopedic disorders in children with MPS and related diseases: a parents' guide. Available at http://www.mpssociety.org/ content/4066/Fact-Sheets/. Accessed May 26, 2010.